Jupiter NEUROSCIENCES, Inc. (JUNS) intrinsic value & 10-year financials
Jupiter NEUROSCIENCES, Inc. (JUNS) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 4 fiscal years revenue reached to $21.8K, with an average return on invested capital of 87.3%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $2.90
- Market cap
- $100.6M
- Revenue (FY2025)
- $21.8K
- ROIC (10-yr avg)
- 87.3%
- Free cash flow (FY2025)
- —
JUNS 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $21.8K | -$8.6M | -$0.25 | — | -40873.2% | — |
| FY2024 | $0 | -$2.4M | -$0.08 | — | — | 91.5% |
| FY2023 | — | -$4.8M | -$0.18 | — | — | 83.1% |
| FY2022 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
JUPITER NEUROSCIENCES, INC. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
JUPITER NEUROSCIENCES, INC. has earned high returns on invested capital, averaging 87.3% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
JUPITER NEUROSCIENCES, INC. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
JUPITER NEUROSCIENCES, INC. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.